Axogen Q2 revenue up 25.6% to $47.9M; net loss narrows; raises FY guidance

Axogen, Inc.

2024-Q2 EPS reported -$0.20 revenue$89,289,000

Revenue $47.9M (+25.6% YoY); net loss $1.9M ($0.04/share) vs $6.7M loss prior year.
Adjusted net income $2.0M ($0.05/share); adjusted EBITDA $5.6M vs loss $0.2M.
FY2024 revenue guidance raised to $182-186M; gross margin guidance adjusted to 74-76%.
Rolling BLA submission for Avance Nerve Graft initiated; expects completion Q3 2024, potential approval mid-2025.
Launched Avive+ Soft Tissue Matrix in June; Core accounts up 18.7% to 412.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.